Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2712-2715

  Houssaye, Serge ^a   Gutmann, Laurent ^a   Varon, Emmanuelle ^a  

^a Ctr Natl de Ref des Pneumoc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; GENE PRODUCT; MOXIFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; GENE MUTATION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; AMINO ACID SUBSTITUTION; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MUTATION;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; QUINOLINES;

EID: 0035992056     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2712-2715.2002     Document Type: Article

References (24)

1. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
2. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates
3. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
4. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program
5. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance
6. Primary targets of fluoroquinolones in Streptococcus pneumoniae
7. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
8. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
9. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the Des-F(6) quinolone BMS-284756
10. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro
11. New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones
12. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
13. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
14. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study
15. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
16. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae
17. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
18. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
19. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
21. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
22. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
23. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
24. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae